Company / Operating Cash Flow per Share
Adaptimmune Therapeutics PLC Operating Cash Flow per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$0.05
FY2024
5-year range
-$0.15 / $0.01
FY2020-FY2024
Trend
+62.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share has fluctuated over the past 9 years, ranging from $-0.19 in FY2018 to $0.01 in FY2021.
Based on SEC 10-K filings.
-0.05 in FY2024.
Improved from $-0.15 to $-0.05 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 62.4% year-over-year.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.05 | +62.4% |
| FY2023 | -$0.14 | +6.5% |
| FY2022 | -$0.15 | -1421.7% |
| FY2021 | $0.01 | +113.6% |
| FY2020 | -$0.08 | +52.6% |
| FY2019 | -$0.18 | +3.4% |
| FY2018 | -$0.19 | -45.2% |
| FY2017 | -$0.13 | -12.7% |
| FY2016 | -$0.11 | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026